Strs Ohio raised its position in shares of Cassava Sciences, Inc. (NASDAQ:SAVA – Get Rating) by 8.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,100 shares of the company’s stock after purchasing an additional 600 shares during the quarter. Strs Ohio’s holdings in Cassava Sciences were worth $338,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State Street Corp boosted its stake in Cassava Sciences by 8.0% during the 1st quarter. State Street Corp now owns 1,053,956 shares of the company’s stock valued at $39,144,000 after purchasing an additional 77,830 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Cassava Sciences by 2.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 273,962 shares of the company’s stock valued at $10,175,000 after purchasing an additional 6,462 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Cassava Sciences by 0.6% during the 1st quarter. Bank of New York Mellon Corp now owns 122,993 shares of the company’s stock valued at $4,568,000 after acquiring an additional 712 shares during the last quarter. Raymond James & Associates lifted its position in shares of Cassava Sciences by 30.3% during the 3rd quarter. Raymond James & Associates now owns 58,686 shares of the company’s stock valued at $2,454,000 after acquiring an additional 13,656 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Cassava Sciences by 94.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 55,866 shares of the company’s stock valued at $1,570,000 after acquiring an additional 27,148 shares during the last quarter. 25.51% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
SAVA has been the subject of a number of recent research reports. B. Riley downgraded Cassava Sciences from a “buy” rating to a “neutral” rating and set a $44.00 price objective for the company. in a research report on Wednesday, November 16th. Univest Sec cut their price objective on Cassava Sciences from $12.00 to $11.00 in a research report on Tuesday, November 29th.
Cassava Sciences Stock Performance
Cassava Sciences (NASDAQ:SAVA – Get Rating) last released its earnings results on Monday, November 7th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). As a group, research analysts forecast that Cassava Sciences, Inc. will post -1.98 EPS for the current fiscal year.
About Cassava Sciences
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
- Get a free copy of the StockNews.com research report on Cassava Sciences (SAVA)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.